Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Peijia MedicalPEJMF 76 Debt-to-EBITDA is -2.31 as of Dec. 2025. GuruFocus rates PEJMF with a GF Score™ of 76/100 and a GF Value™ of $2.75. The stock has 4 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Peijia Medical ranks worse than 214132.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Peijia Medical's Debt-to-EBITDA or its related term are showing as below:
PEJMF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.54 Med: -0.2 Max: 0
Current: -3.54
PEJMF's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs PEJMF: -3.54
Peijia Medical (OTCPK:PEJMF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Peijia Medical Debt-to-EBITDA Related Terms
Peijia Medical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Peijia Medical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Peijia Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peijia Medical Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Peijia Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Peijia Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Peijia Medical (PEJMF) has a Debt-to-EBITDA of -2.31 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Peijia Medical. According to the industry distribution chart, Peijia Medical ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Peijia Medical's Debt-to-EBITDA too high?
Peijia Medical's current Debt-to-EBITDA is -2.31. Based on the distribution chart, Peijia Medical ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Peijia Medical has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Peijia Medical's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Peijia Medical ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Peijia Medical in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Peijia Medical. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peijia Medical's current Debt-to-EBITDA is -2.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peijia Medical stock overvalued right now?
Peijia Medical (PEJMF) has a current Debt-to-EBITDA of -2.31. The stock's GF Value™ is $2.75, compared to a current price of $1.39 — trading 49.6% below its estimated fair value. The current Debt-to-EBITDA is -2.31. Peijia Medical's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Peijia Medical (PEJMF), the current Debt-to-EBITDA is -2.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Peijia Medical (PEJMF) Overvalued in 2026?
Based on GuruFocus' analysis, Peijia Medical stock appears to be undervalued.
The current stock price of $1.39 is trading 49.6% below its estimated GF Value™ of $2.75.
Key valuation signals for PEJMF:
Debt-to-EBITDA: -2.31
GF Value™: $2.75 vs. price of $1.39 (49.6% below fair value)
No single metric tells the full story. See the PEJMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Peijia Medical Ltdis a provider of inventive medical products and solutions. It focuses on the high-growth interventional procedural medical device market in China. Its products and product candidates target large, fast-growing and under-penetrated markets with high entry barriers, including the transcatheter valve therapeutic medical device market and the neurointerventional procedural medical device market. The Company's product pipeline consists of transcatheter valve therapeutic and neurointerventional products and product candidates spanning three key business segments: Transcatheter Valve Therapeutic Business, Future Technology Business and Neurointerventional Business.
76GF Score
Get the complete analysis for PEJMF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PEJMF has been successfully added to your 
